Puri Sonam, Shafique Michael
Division of Medical Oncology, Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, USA.
Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Drugs Context. 2020 Jan 13;9. doi: 10.7573/dic.2019-9-2. eCollection 2020.
Immunotherapy has revolutionized cancer treatment. In non-small-cell lung cancer (NSCLC), monotherapy with immune checkpoint inhibitors has improved survival in metastatic disease. Combinations of immune checkpoint inhibitors have shown synergy in preclinical models and are being studied as part of the treatment armamentarium in NSCLC. This review discusses the rationale, outcomes, and challenges of combination immune checkpoint blockade. Despite the challenges, this paper also presents some solutions and ways to improve our understanding and implementation of such combinations in the future.
免疫疗法彻底改变了癌症治疗方式。在非小细胞肺癌（NSCLC）中，免疫检查点抑制剂单药治疗已改善了转移性疾病患者的生存率。免疫检查点抑制剂联合治疗在临床前模型中已显示出协同作用，目前正在作为NSCLC治疗手段的一部分进行研究。本综述讨论了联合免疫检查点阻断的基本原理、疗效及挑战。尽管存在挑战，但本文也提出了一些解决方案以及未来增进对此类联合治疗的理解与应用的方法。
